Lancet Respir Med
http://www.ncbi.nlm.nih.gov/pubmed/28145234
5(2):e10
https://connects.catalyst.harvard.edu/Profiles/profile/101575144
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC.
Lancet Respir Med
http://www.ncbi.nlm.nih.gov/pubmed/28145234
5(2):e10
https://connects.catalyst.harvard.edu/Profiles/profile/101575144